A Phase 1 interventional study of Elamipretide in Age-Related Macular Degeneration, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2020-10-20.
Sponsored by Stealth BioTherapeutics Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 286th largest by enrollment of the 491 interventional ones that give a count, is one of 19 that started in 2016, is one of 91 in phase 1, and was the 349th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 19 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 5 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, Phase 1 single-center study in approximately 40 subjects who have 1 eye with intermediate AMD, including a high-risk drusen without geographic atrophy (GA) subgroup and a noncentral GA subgroup. Eligible subjects will receive 40 mg of elamipretide administered as a once daily 1.0 mL subcutaneous injection for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For this study, only 1 eye of an eligible subject will be included and designated as the study eye. However, all specified ophthalmic testing will be performed on both eyes at each time point. A potential subject must meet the following criteria to be eligible for inclusion in the study:
Intermediate AMD - noncentral GA disease group:
Geographic atrophy may be multifocal, but the cumulative GA lesion size must be:
Presence of measurable hyperautofluorescence adjacent to the discrete foci of GA.
OR
Intermediate AMD - high-risk drusen without GA disease group:
High-risk drusen is defined as presence of either at least 1 large (≥ 125 µm) druse or multiple medium-size (between 63 and 124 µm) drusen.
General (both disease groups):
If of childbearing potential or in a relationship with a partner of childbearing potential, are able to abstain from sex or use acceptable during the study and for 3 months after dosing.
Exclusion Criteria:
A subject with study eye who meets any of the following criteria will be excluded from the study:
Ocular conditions - study eye
Previous intravitreal drug delivery (e.g., intravitreal injection, anti-angiogenic drugs, or device implantation) in the study eye.
Ocular conditions - either eye
Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
Systemic conditions
Presence or history of allergy disease requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.
General
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants had one 1 eye with intermediate age-related macular degeneration with high-risk drusen without geographic atrophy \[GA\]), i.e. the presence of either at least 1 large (≥125 μm) druse or multiple medium-size (63-124 μm) drusen. Participants received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
Drug: Elamipretide
Participants had 1 eye with intermediate AMD with noncentral geographic atrophy \[NCGA\]; i.e. evidence of GA with cumulative area ≥1.27 mm2 (approximately 0.5 disc area\[DA\]) by fundus autofluorescence (FAF) that spared the fovea (defined as retinal pigment epithelium (RPE) and outer retina intact by spectral-domain optical coherence tomography \[SD-OCT\]). Participants in this arm also received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
Drug: Elamipretide
40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
Also known as: MTP-131; Bendavia
Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA)
Change from Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) at 4 meters, letters from Baseline to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.
Time frame: Day 0 (Baseline to Day 7, and to Weeks 4, 8, 12, 16, 20, 24, and 28.
Change From Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA)
Change from Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA) from Baseline (Day 0) to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.
Time frame: Baseline to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.
Change From Baseline in Mean Dark Adaptometry
Change from Baseline in Mean Dark Adaptometry from Baseline to Week 24- at 0% 25%, 50%, 75% Bleach Level. Dark adaptometry, used to evaluate night blindness by measuring the absolute thresholds of rod sensitivity, was performed within 14 days before Day 0 and at all in-person visits except for Day 7. Dark adaptation is the delayed recovery of light sensitivity in darkness following prior light exposure (photobleaching). The observed and change from baseline recovery scores (in minutes) for each bleach level (0%, 25%, 50%, and 75%) were summarized descriptively for each eye at each visit and were presented in a listing. Shorter recovery times are better than longer recovery times.
Time frame: Baseline (Day 0) and Week 24
Mean Treatment Compliance (%) of Administration of Subcutaneous Elamipretide
Mean percentage of treatment compliance of administration of subcutaneous elamipretide. The number of injections (diary) and vials used was used to compute % compliance over the duration of the subject's participation in the trial. Percentage can range from 0-100%, where 0% means the participant followed the correct dosing 0% of the time, and 100% compliance means the participant followed the correct dosing 100% of the time, with a higher % meaning a better outcome.
Time frame: Baseline through Week 28
Mean Number of Home Health Visits to Administer Elamipretide
Mean Number of Home Health Visits Necessary for Participant or Caregiver to Learn How to Administer Elamipretide
Time frame: Baseline (Day 0) through Week 24
Change From Baseline in Mean Area of Geographic Atrophy by Fundus Autofluorescence
Change from Baseline in Mean Area of Geographic Atrophy (GA) by Fundus Autofluorescence (FAF) at Week 24. Fluorescein angiography (FA) was used to examine the circulation of the retina and choroid using fluorescein dye and a specialized camera to trace the dye. Fundus autofluorescence imaging of the retinal pigment epithelium and neurosensory retina was performed within 14 days of Day 0 and at every visit with the exception of Day 0 and Day 7. Atrophy is characterized by loss of the retinal pigment epithelium (RPE), overlying photoreceptors and underlying choriocapillaris. Greater area affected means a worse outcome than smaller area affected.
Time frame: Baseline (Day 0) to Week 24
Change From Baseline in Mean Area of Geographic Atrophy as Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)
Change from Baseline in Mean Area of Geographic Atrophy by Sector as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) at Week 24
Time frame: Baseline to Week 24
Change From Baseline in Mean Reading Acuity Test: With Standard Luminance
Change from Baseline in Mean Reading Acuity Test: Mean Critical Print Size with Standard Luminance in Weeks 4, 8, 12, 16, 20, 24 and 28 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.
Time frame: Baseline and Weeks 4, 8, 12, 16 20, 24 and 28
Change From Baseline in Mean Reading Acuity Test: Low Luminance
Change from Baseline in Mean Reading Acuity Test: Mean Critical Print Size with Low Luminance in Weeks 4, 8, 12, 16, 20, 24 and 28 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.
Time frame: Assessed at screening, baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28
Change From Baseline in National Eye Institute Visual Function Questionnaire-39 (VFQ-39) Score Standard Luminance
Change from baseline (Day 0) at Week 12, 24 and 28. National Eye Institute Visual Function Questionnaire-39 (VFQ-39) score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at baseline (Day 0), Week 12, Week 24 and Week 28
Change From Baseline in Mean Low Luminance Questionnaire (LLQ) Score
Change from baseline (Day 0) at Week 12, Week 24, and Week 28 in LLQ score. The LLQ is a 32-item questionnaire with six subscales related to low luminance settings: driving, mobility, extreme lighting, general dim lighting, and peripheral vision. Each question is scored on a scale ranging from 0, or maximal difficulty, to 100, or no difficulty in low luminance settings. Higher scores mean better functioning. The questions are assigned to different subscales and are averaged to generate one score per subscale. After weighting each subscale for the number of questions, the weighted subscales are averaged to generate a composite LLQ score.
Time frame: Baseline (Day 0), Week 12, and Week 24 and Week 28
Change From Baseline in Mean Mesopic Light Sensitivity
Change from baseline in mean mesopic light sensitivity for Weeks, 4, 8, 12, 16, 20, and 24 as assessed by microperimetry for number of loci \<25dB and \<14dB. Mesopic microperimetry, used to measure retinal sensitivity, was performed within 14 days before Day 0 and at all in-person visits except for Day 7.
Time frame: Baseline (Day 0) and Weeks 4,8,12,16,20,and 24
Change From Baseline in Mean Retinal Pigment Epithelium - Drusen Complex (RPEDC) Thickness as Measured by SD-OCT
Change from baseline in mean retinal pigment epithelium - drusen complex (RPEDC) thickness as Measured by SD-OCT by sector at Week 24
Time frame: Baseline (Day 0) and Week 24
Change From Baseline in Mean Retinal Pigment Epithelium-Drusen Complex Volume
Change from baseline in mean Retinal Pigment Epithelium-Drusen Complex volume at Week 24 by sector
Time frame: Baseline (Day 0) to Week 24
| Milestone | High-Risk Drusen (HRD) | NCGA (Noncentral GA) |
|---|---|---|
| Started | 21 | 19 |
| Completed | 18 | 15 |
| Not completed | 3 | 4 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow up | 1 | 0 |
Change from Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) at 4 meters, letters from Baseline to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.
| letters | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Day 7 | 0.810 ± 4.8746 | 0.526 ± 4.1281 |
| Week 4 | 2.762 ± 5.5759 | 1.833 ± 5.0904 |
| Week 8 | 1.950 ± 4.4066 | 1.556 ± 6.2987 |
| Week 12 | 1.150 ± 5.5845 | 1.438 ± 5.4156 |
| Week 16 | 2.789 ± 5.8933 | 2.813 ± 5.5883 |
| Week 20 | 3.842 ± 4.1401 | 1.438 ± 5.7847 |
| Week 24 | 3.579 ± 6.3972 | 4.600 ± 5.0681 |
| Week 28 | 1.333 ± 10.4881 | 3.667 ± 5.8023 |
Change from Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA) from Baseline (Day 0) to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.
| letters | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Day 7 | 2.714 ± 5.3399 | 1.105 ± 8.4518 |
| Week 4 | 2.762 ± 4.8673 | 5.000 ± 5.5413 |
| Week 8 | 2.800 ± 6.2205 | 4.167 ± 4.2183 |
| Week 12 | 2.150 ± 6.6986 | 4.688 ± 4.5858 |
| Week 16 | 5.158 ± 7.3126 | 4.875 ± 5.9203 |
| Week 20 | 5.632 ± 7.4923 | 5.438 ± 5.8875 |
| Week 24 | 5.632 ± 7.7832 | 5.400 ± 7.8540 |
| Week 28 | 2.556 ± 14.2095 | 3.733 ± 8.1545 |
Change from Baseline in Mean Dark Adaptometry from Baseline to Week 24- at 0% 25%, 50%, 75% Bleach Level. Dark adaptometry, used to evaluate night blindness by measuring the absolute thresholds of rod sensitivity, was performed within 14 days before Day 0 and at all in-person visits except for Day 7. Dark adaptation is the delayed recovery of light sensitivity in darkness following prior light exposure (photobleaching). The observed and change from baseline recovery scores (in minutes) for each bleach level (0%, 25%, 50%, and 75%) were summarized descriptively for each eye at each visit and were presented in a listing. Shorter recovery times are better than longer recovery times.
| minutes | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| 0% Bleach Level | -11.553 ± 10.3229 | 3.543 ± 5.0140 |
| 25% Bleach Level | 0.409 ± 4.2798 | 8.3302 ± 0.000 |
| 50% Bleach Level | 0.000 ± 0.0000 | -3.263 ± 7.9935 |
| 75% Bleach Level | 1.562 ± 5.3936 | -3.048 ± 9.1675 |
Mean percentage of treatment compliance of administration of subcutaneous elamipretide. The number of injections (diary) and vials used was used to compute % compliance over the duration of the subject's participation in the trial. Percentage can range from 0-100%, where 0% means the participant followed the correct dosing 0% of the time, and 100% compliance means the participant followed the correct dosing 100% of the time, with a higher % meaning a better outcome.
| % of compliance in study dosing | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Mean Treatment Compliance (%) of Administration of Subcutaneous Elamipretide | 98.4 ± 4.04 | 97.3 ± 6.70 |
Mean Number of Home Health Visits Necessary for Participant or Caregiver to Learn How to Administer Elamipretide
| visits | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Mean Number of Home Health Visits to Administer Elamipretide | 2.2 ± 0.54 | 2.5 ± 1.02 |
Change from Baseline in Mean Area of Geographic Atrophy (GA) by Fundus Autofluorescence (FAF) at Week 24. Fluorescein angiography (FA) was used to examine the circulation of the retina and choroid using fluorescein dye and a specialized camera to trace the dye. Fundus autofluorescence imaging of the retinal pigment epithelium and neurosensory retina was performed within 14 days of Day 0 and at every visit with the exception of Day 0 and Day 7. Atrophy is characterized by loss of the retinal pigment epithelium (RPE), overlying photoreceptors and underlying choriocapillaris. Greater area affected means a worse outcome than smaller area affected.
| mm^2 | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Week 12 | — | 0.264 ± 0.1641 |
| Week 24 | — | 0.503 ± 0.4914 |
Change from Baseline in Mean Area of Geographic Atrophy by Sector as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) at Week 24
| mm^2 | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Center Sector | — | 0.02 ± 0.048 |
| Inner Superior | — | 0.05 ± 0.096 |
| Inner Nasal | — | 0.04 ± 0.059 |
| Inner Inferior | — | 0.02 ± 0.073 |
| Inner Temporal | — | 0.05 ± 0.097 |
| Outer Superior | — | 0.08 ± 0.116 |
| Outer Nasal | — | 0.06 ± 0.114 |
| Outer Inferior | — | 0.05 ± 0.146 |
| Outer Temporal | — | 0.08 ± 0.129 |
| Total ETDRS grid | — | 0.45 ± 0.607 |
Change from Baseline in Mean Reading Acuity Test: Mean Critical Print Size with Standard Luminance in Weeks 4, 8, 12, 16, 20, 24 and 28 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.
| units on a scale | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Week 4 | -0.04 ± 0.121 | -0.03 ± 0.091 |
| Week 8 | -0.08 ± 0.111 | -0.02 ± 0.115 |
| Week 12 | -0.10 ± 0.156 | -0.02 ± 0.098 |
| Week 16 | -0.11 ± 0.151 | -0.06 ± 0.115 |
| Week 20 | -0.12 ± 0.126 | -0.01 ± 0.109 |
| Week 24 | -0.11 ± 0.152 | -0.02 ± 0.126 |
| Week 28 | -0.04 ± 0.201 | 0.01 ± 0.173 |
Change from Baseline in Mean Reading Acuity Test: Mean Critical Print Size with Low Luminance in Weeks 4, 8, 12, 16, 20, 24 and 28 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.
| units on a scale | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Week 4 | -0.11 ± 0.170 | -0.09 ± 0.088 |
| Week 8 | -0.16 ± 0.179 | -0.10 ± 0.253 |
| Week 12 | -0.21 ± 0.177 | -0.20 ± 0.236 |
| Week 16 | -0.25 ± 0.209 | -0.16 ± 0.232 |
| Week 20 | -0.29 ± 0.184 | -0.14 ± 0.171 |
| Week 24 | -0.28 ± 0.174 | -0.11 ± 0.209 |
| Week 28 | -0.24 ± 0.238 | -0.10 ± 0.194 |
Change from baseline (Day 0) at Week 12, 24 and 28. National Eye Institute Visual Function Questionnaire-39 (VFQ-39) score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Week 12 Color Vision | 8.8 ± 18.63 | 10.9 ± 20.35 |
| Week 12 Composite | 7.6 ± 7.47 | 5.5 ± 8.90 |
| Week 12 Dependency | 1.9 ± 10.94 | 2.0 ± 14.02 |
| Week 12 Distance Activities | 7.0 ± 8.13 | 4.6 ± 12.19 |
| Week 12 Driving | 10.0 ± 12.85 | 0.6 ± 13.38 |
| Week 12 General Health | 1.4 ± 8.98 | 1.9 ± 9.33 |
| Week 12 General Vision | 5.3 ± 11.18 | 7.2 ± 14.02 |
| Week 12 Mental Health | 9.3 ± 13.79 | 9.1 ± 14.63 |
| Week 12 Near Activities | 8.2 ± 10.43 | 2.4 ± 11.51 |
| Week 12 Ocular Pain | 7.5 ± 20.84 | 3.1 ± 9.68 |
| Week 12 Peripheral Vision | 12.5 ± 19.02 | 7.8 ± 19.83 |
| Week 12 Role Difficulties | 5.9 ± 12.25 | 5.9 ± 26.37 |
| Week 12 Social Functioning | 7.5 ± 8.51 | 5.2 ± 18.48 |
| Week 24 Color Vision | 11.8 ± 22.62 | 11.7 ± 26.50 |
| Week 24 Composite | 9.2 ± 9.19 | 7.0 ± 9.38 |
| Week 24 Dependency | 2.3 ± 14.61 | 6.7 ± 10.94 |
| Week 24 Distance Activities | 8.4 ± 11.11 | 4.7 ± 16.13 |
| Week 24 Driving | 14.5 ± 14.66 | 0.6 ± 10.46 |
| Week 24 General Health | -0.3 ± 9.01 | 3.3 ± 10.21 |
| Week 24 General Vision | 8.7 ± 12.78 | 6.3 ± 13.69 |
| Week 24 Mental Health | 9.5 ± 17.55 | 7.7 ± 9.80 |
| Week 24 Near Activities | 9.8 ± 11.00 | 5.6 ± 13.84 |
| Week 24 Ocular Pain | 5.9 ± 19.26 | 5.0 ± 14.02 |
| Week 24 Peripheral Vision | 17.1 ± 16.78 | 15.0 ± 18.42 |
| Week 24 Role Difficulties | 6.9 ± 11.58 | 5.8 ± 17.27 |
| Week 24 Social Functioning | 6.6 ± 10.96 | 5.6 ± 15.64 |
| Week 28 Color Vision | 12.5 ± 17.68 | 5.0 ± 28.66 |
| Week 28 Composite | 7.9 ± 14.04 | 4.3 ± 10.46 |
| Week 28 Dependency | 1.7 ± 17.91 | -1.3 ± 20.07 |
| Week 28 Distance Activities | 5.7 ± 16.92 | 7.1 ± 13.95 |
| Week 28 Driving | 12.3 ± 12.54 | 0.8 ± 9.47 |
| Week 28 General Health | 4.2 ± 10.18 | 4.0 ± 9.20 |
| Week 28 General Vision | 8.6 ± 16.25 | 3.7 ± 12.60 |
| Week 28 Mental Health | 9.4 ± 19.84 | 5.7 ± 10.50 |
| Week 28 Near Activities | 6.0 ± 20.17 | 1.7 ± 12.63 |
| Week 28 Ocular Pain | 7.6 ± 20.17 | 0.0 ± 14.94 |
| Week 28 Peripheral Vision | 15.3 ± 21.25 | 13.3 ± 20.85 |
| Week 28 Role Difficulties | 4.2 ± 21.00 | 5.4 ± 20.03 |
| Week 28 Social Functioning | 5.6 ± 17.85 | 3.3 ± 10.82 |
Change from baseline (Day 0) at Week 12, Week 24, and Week 28 in LLQ score. The LLQ is a 32-item questionnaire with six subscales related to low luminance settings: driving, mobility, extreme lighting, general dim lighting, and peripheral vision. Each question is scored on a scale ranging from 0, or maximal difficulty, to 100, or no difficulty in low luminance settings. Higher scores mean better functioning. The questions are assigned to different subscales and are averaged to generate one score per subscale. After weighting each subscale for the number of questions, the weighted subscales are averaged to generate a composite LLQ score.
| score on a scale | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Week 12 Control questions | 10.5 ± 15.47 | -2.3 ± 9.86 |
| Week 12 Dim light reading | 9.7 ± 12.58 | 4.3 ± 13.05 |
| Week 12 Driving or riding in car | 12.2 ± 16.41 | 3.9 ± 10.92 |
| Week 12 General dim light vision | 11.9 ± 13.26 | 6.9 ± 12.62 |
| Week 12 Light transitions and glare | 9.3 ± 15.07 | 6.3 ± 13.35 |
| Week 12 Mobility | 6.7 ± 11.66 | 6.3 ± 10.32 |
| Week 12 Other Activities of Daily Living (ADLs) | 11.5 ± 18.36 | 10.2 ± 15.29 |
| Week 12 Peripheral vision | 16.3 ± 19.49 | 3.9 ± 17.51 |
| Week 24 Control questions | 7.2 ± 12.56 | 0.7 ± 12.47 |
| Week 24 Dim light reading | 15.8 ± 14.34 | 7.1 ± 11.30 |
| Week 24 Driving or riding in car | 16.4 ± 18.77 | 4.2 ± 14.11 |
| Week 24 General dim light vision | 15.6 ± 15.17 | 7.7 ± 12.10 |
| Week 24 Light transitions and glare | 17.4 ± 13.98 | 6.7 ± 13.71 |
| Week 24 Mobility | 9.6 ± 20.27 | 2.8 ± 16.57 |
| Week 24 Other Activities of Daily Living (ADLs) | 17.8 ± 17.95 | 10.4 ± 20.82 |
| Week 24 Peripheral vision | 17.8 ± 20.12 | 5.8 ± 24.03 |
| Week 28 Control Questions | 3.2 ± 18.44 | 0.2 ± 14.25 |
| Week 28 Dim light reading | 12.2 ± 19.70 | 7.1 ± 12.47 |
| Week 28 Driving or riding in car | 10.8 ± 23.85 | 4.3 ± 14.34 |
| Week 28 General dim light vision | 11.7 ± 19.43 | 3.3 ± 10.73 |
| Week 28 Light transitions and glare | 15.0 ± 14.75 | 5.3 ± 14.07 |
| Week 28 Mobility | 7.4 ± 23.02 | -1.1 ± 14.39 |
| Week 28 Other Activities of Daily Living | 12.2 ± 23.82 | 3.8 ± 13.73 |
| Week 28 Peripheral Vision | 13.9 ± 20.06 | 5.0 ± 15.53 |
Change from baseline in mean mesopic light sensitivity for Weeks, 4, 8, 12, 16, 20, and 24 as assessed by microperimetry for number of loci \<25dB and \<14dB. Mesopic microperimetry, used to measure retinal sensitivity, was performed within 14 days before Day 0 and at all in-person visits except for Day 7.
| loci | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Number of loci <25dB Week 4 | 0.6 ± 6.08 | 0.6 ± 1.79 |
| Number of loci <25dB Week 8 | 1.3 ± 8.21 | 0.7 ± 1.94 |
| Number of loci <25dB Week 12 | 0.5 ± 7.87 | 0.1 ± 3.09 |
| Number of loci <25dB Week 16 | 0.9 ± 8.56 | 0.1 ± 2.35 |
| Number of loci <25dB Week 20 | -1.2 ± 5.88 | -0.1 ± 1.44 |
| Number of loci <25dB Week 24 | -0.5 ± 8.27 | -0.1 ± 3.45 |
| Number of loci <14dB Week 4 | 0.3 ± 0.3 | 1.7 ± 1.7 |
| Number of loci <14dB Week 8 | -1.4 ± 3.65 | 1.7 ± 4.89 |
| Number of loci <14dB Week 12 | 1.3 ± 10.05 | 3.2 ± 5.90 |
| Number of loci <14dB Week 16 | -2.5 ± 2.38 | 1.5 ± 5.01 |
| Number of loci <14dB Week 20 | -0.2 ± 6.14 | 1.5 ± 4.88 |
| Number of loci <14dB Week 24 | -0.3 ± 8.30 | 3.3 ± 5.82 |
Change from baseline in mean retinal pigment epithelium - drusen complex (RPEDC) thickness as Measured by SD-OCT by sector at Week 24
| um | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Center | 0.57 ± 5.147 | 0.38 ± 4.137 |
| Inner Superior | 1.29 ± 3.699 | -0.85 ± 2.389 |
| Inner Nasal | 1.43 ± 3.143 | -0.83 ± 2.801 |
| Inner Inferior | 0.72 ± 4.393 | -0.82 ± 3.798 |
| Inner temporal | 1.00 ± 3.680 | -0.34 ± 2.897 |
| Outer Superior | 0.34 ± 2.279 | -0.10 ± 1.580 |
| Outer Nasal | 0.34 ± 2.301 | -0.09 ± 1.919 |
| Outer Inferior | -0.19 ± 2.356 | -0.04 ± 2.023 |
| Outer Temporal | 0.25 ± 2.672 | -0.04 ± 1.594 |
| Total ETDRS | 0.39 ± 1.885 | -0.25 ± 1.590 |
Change from baseline in mean Retinal Pigment Epithelium-Drusen Complex volume at Week 24 by sector
| mm^3 | AMD-High-Risk Drusen (HRD) | AMD-NCGA (Noncentral GA) |
|---|---|---|
| Center | 0.00 ± 0.004 | 0.00 ± 0.003 |
| Inner superior | 0.00 ± 0.006 | -0.00 ± 0.004 |
| Inner nasal | 0.00 ± 0.005 | -0.00 ± 0.004 |
| Inner inferior | 0.00 ± 0.007 | -0.00 ± 0.006 |
| Inner temporal | 0.00 ± 0.006 | -0.00 ± 0.005 |
| Outer superior | 0.00 ± 0.012 | -0.00 ± 0.008 |
| Outer nasal | 0.00 ± 0.012 | -0.00 ± 0.010 |
| Outer inferior | -0.00 ± 0.012 | -0.00 ± 0.011 |
| Outer temporal | 0.00 ± 0.014 | -0.00 ± 0.009 |
| Total ETDRS | 0.01 ± 0.054 | -0.01 ± 0.046 |
Collected over 28 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High-Risk Drusen (HRD) | 0/21 (0%) | 1/21 (4.8%) | 21/21 (100%) |
| NCGA (Noncentral GA) | 0/19 (0%) | 1/19 (5.3%) | 19/19 (100%) |
| Event | High-Risk Drusen (HRD) | NCGA (Noncentral GA) |
|---|---|---|
| Urinary tract infectionInfections and infestations | 0/21 | 1/19 |
| SepsisInfections and infestations | 0/21 | 1/19 |
| Calculus urinaryRenal and urinary disorders | 1/21 | 0/19 |
| Event | High-Risk Drusen (HRD) | NCGA (Noncentral GA) |
|---|---|---|
| Injection site pruritisGeneral disorders | 21/21 | 17/19 |
| Injection site bruisingGeneral disorders | 16/21 | 13/19 |
| Injection site erythemaGeneral disorders | 16/21 | 14/19 |
| Injection site indurationGeneral disorders | 16/21 | 14/19 |
| Injection site painGeneral disorders | 9/21 | 6/19 |
| Injection site haemorrhageGeneral disorders | 6/21 | 7/19 |
| Upper respiratory tract infectionInfections and infestations | 7/21 | 3/19 |
| Injection site urticariaGeneral disorders | 5/21 | 4/19 |
| Punctate keratitisEye disorders | 3/21 | 0/19 |
| NauseaGastrointestinal disorders | 1/21 | 2/19 |
| Age, Continuous(years) | High-Risk Drusen (HRD) | NCGA (Noncentral GA) | Total |
|---|---|---|---|
| Mean | 70.9 ± 8.54 | 76.0 ± 8.22 | 73.3 ± 8.67 |
| Sex: Female, Male(Participants) | High-Risk Drusen (HRD) | NCGA (Noncentral GA) | Total |
|---|---|---|---|
| Female | 13 | 11 | 24 |
| Male | 8 | 8 | 16 |
| Ethnicity (NIH/OMB)(Participants) | High-Risk Drusen (HRD) | NCGA (Noncentral GA) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 20 | 18 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | High-Risk Drusen (HRD) | NCGA (Noncentral GA) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 21 | 19 | 40 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Smoking Status(Participants) | High-Risk Drusen (HRD) | NCGA (Noncentral GA) | Total |
|---|---|---|---|
| Never smoker | 13 | 8 | 21 |
| Former smoker | 8 | 11 | 19 |
| Current smoker | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2016 to primary completion in Mar 2018, 16 months.
Results were first posted in Sep 2020, 2 years 6 months after primary completion.
Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 16 months is close to that.
Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →